Skip to main content

Table 1 Characteristics of the HIV-1-infected study participants

From: HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL

Subject Age Sex CD4 count (cells/mm3) VL (RNA/ml) TC (mg/dl) HDL (mg/dl) LDL (mg/dl) TG (mg/dl) HII (sham) HII (L-4F) ART
1 25 M 367 < 50 135 51 66 91 2.45 0.75 AZV, RTV, TDF, FTC
2 NA M NA NA NA NA NA NA 2.69 1.19 NA
3 57 M 499 < 50 159 31 77 254 1.01 0.69 EFV, ABC, 3TC
4 44 M 540 < 50 NA NA NA NA 2.73 0.96 TDF, FTC, RTV, FPV
5 44 M 540 < 50 286 26 212 240 2.55 0.93 TDF, FTC, AZV, RTV
6 46 M 571 < 50 184 52 108 121 1.82 0.89 NA
7 47 M 966 < 50 176 52 122 100 2.61 0.86 TDF, FTC, NVP
8 31 M 553 < 50 205 76* 109 98 1.24 0.64 EFV, FTC, TDF
9 21 M 712 < 50 169 64* 93 58 1.95 1.00 EFV, FTC, TDF
10 62 M 605 < 50 167 44 88 176 2.57 1.00 LPV, RTV, 3TC ETV
  1. Abbreviations: AZV: Atazanavir; ABC: Abacavir; ART: Antiretroviral therapy; ETV: Etravirine; Efavirenz (EFV), FTC: Emtricitabine, FPV: Fosamprenavir; HDL: High Density Lipoprotein; HII; HDL Inflammatory Index; 3TC: Lamivudine; LPV: lopinavir; LDL: Low Density Lipoprotein; M: Male; NVP: Nevirapine; NA: Not available; TDF: Tenofovir; TC: Total Cholesterol; TG: Triglycerides; RTV: Ritonavir; VL: Viral Load
  2. *:Samples were collected when patients were non-fasting.